Key Takeaways: CStone's CS2009 trispecific antibody achieved an 81.3% ORR in PD-L1-high NSCLC patients. PD-L1-negative patients recorded a 100% ORR when combined with chemotherapy. The data validates the PD-1/VEGF/CTLA-4 triple-target approach in a $20B-plus NSCLC market.
A trispecific antibody targeting PD-1, VEGF and CTLA-4 delivered an 81.3% objective response rate in first-line NSCLC patients with high PD-L1 expression, data from CStone Pharmaceuticals show.
CStone Pharmaceuticals' CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, achieved an 81.3% objective response rate and a 100% disease control rate as monotherapy in first-line non-small cell lung cancer patients with PD-L1 tumor proportion score of 50% or higher, according to updated Phase 1/2 data presented at the American Society of Clinical Oncology annual meeting on Sunday.
The response was consistent across histologies, with squamous cell patients achieving an 87.5% ORR and non-squamous patients a 75% ORR, the Shanghai-based company said. In the PD-L1-negative or low-expression subgroup — patients with TPS of 5% or less — CS2009 combined with chemotherapy produced a 75% ORR and 100% DCR among squamous NSCLC patients. Notably, PD-L1-negative patients within that cohort recorded a 100% ORR, though the company cautioned that follow-up remains short and the efficacy readout is immature.
CS2009 is designed to simultaneously block three immune evasion pathways: PD-1 checkpoint inhibition, VEGF-driven angiogenesis and CTLA-4-mediated T-cell suppression. Most bispecific antibodies in development target only two of these mechanisms — Akeso's ivonescimab, for instance, blocks PD-1 and VEGF but not CTLA-4. By adding a third target, CStone aims to overcome resistance mechanisms that limit the durability of existing immunotherapies.
The trispecific approach carries higher development risk. Manufacturing three functional binding domains in a single molecule is technically challenging, and the broader mechanism raises the potential for immune-related adverse events. CStone did not disclose detailed safety data in its ASCO presentation, and the full toxicity profile will be critical for regulators assessing whether the added complexity translates into a meaningful therapeutic advantage over established PD-1 inhibitors and emerging bispecifics.
The NSCLC market represents one of oncology's largest opportunities, with more than 2.2 million new cases diagnosed globally each year and roughly 85% classified as non-small cell. First-line immunotherapy combinations have become the standard of care, but response rates in PD-L1-negative patients remain low — typically below 50% with PD-1 plus chemotherapy alone. A drug that can deliver a 100% ORR in that subgroup, even in a small early-stage cohort, would address a significant unmet need if confirmed in larger trials.
CStone's cash position will determine how quickly it can advance CS2009 into registrational studies. The company reported 1.46 billion yuan ($202 million) in cash and equivalents as of December 2025, according to its annual filing, providing runway through at least 2027. A partnership with a larger pharmaceutical company could accelerate development and de-risk the program, particularly given the manufacturing complexity of trispecific antibodies.
The broader immuno-oncology field is watching the trispecific platform closely. If CS2009's early efficacy holds in later-stage trials, it could challenge the current PD-1-plus-chemo standard of care and pressure companies developing bispecific approaches. Akeso's ivonescimab, which recently demonstrated a 34% improvement in overall survival against a PD-1 inhibitor in squamous NSCLC, has already raised the bar for what novel immunotherapy formats must achieve.
This article is for informational purposes only and does not constitute investment advice.
